Leveraging Antibody, B Cell and Fc Receptor Interactions to Understand Heterogeneous Immune Responses in Tuberculosis
Overview
Authors
Affiliations
Despite over a century of research, , the causative agent of tuberculosis (TB), continues to kill 1.5 million people annually. Though less than 10% of infected individuals develop active disease, the specific host immune responses that lead to transmission and death, as well as those that are protective, are not yet fully defined. Recent immune correlative studies demonstrate that the spectrum of infection and disease is more heterogenous than has been classically defined. Moreover, emerging translational and animal model data attribute a diverse immune repertoire to TB outcomes. Thus, protective and detrimental immune responses to likely encompass a framework that is broader than T helper type 1 (Th1) immunity. Antibodies, Fc receptor interactions and B cells are underexplored host responses to . Poised at the interface of initial bacterial host interactions and in granulomatous lesions, antibodies and Fc receptors expressed on macrophages, neutrophils, dendritic cells, natural killer cells, T and B cells have the potential to influence local and systemic adaptive immune responses. Broadening the paradigm of protective immunity will offer new paths to improve diagnostics and vaccines to reduce the morbidity and mortality of TB.
Long non-coding RNA transcripts in -host interactions.
Vijayaraghavan M, Gadad S, Dhandayuthapani S Noncoding RNA Res. 2025; 11:281-293.
PMID: 39926616 PMC: 11803167. DOI: 10.1016/j.ncrna.2024.12.005.
Immune correlates of protection as a game changer in tuberculosis vaccine development.
Wang J, Fan X, Hu Z NPJ Vaccines. 2024; 9(1):208.
PMID: 39478007 PMC: 11526030. DOI: 10.1038/s41541-024-01004-w.
Immunogenicity and Protective Efficacy of a Multi-Antigen Subunit Vaccine in Mice.
Nisa A, Pinto R, Britton W, Triccas J, Counoupas C Vaccines (Basel). 2024; 12(9).
PMID: 39340027 PMC: 11435920. DOI: 10.3390/vaccines12090997.
Antibodies as key mediators of protection against .
Wang Q, Nag D, Baldwin S, Coler R, McNamara R Front Immunol. 2024; 15:1430955.
PMID: 39286260 PMC: 11402706. DOI: 10.3389/fimmu.2024.1430955.
Neudecker D, Fritschi N, Sutter T, Lu L, Lu P, Tebruegge M BMC Infect Dis. 2024; 24(1):481.
PMID: 38730343 PMC: 11084122. DOI: 10.1186/s12879-024-09359-0.